ML García Vivar

Effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors and factors associated with response in psoriatic arthritis with axial involvement: the APxis-IL12-23 study

OBJECTIVES: To assess the real-world effectiveness of two interleukin (IL)-23 inhibitors [guselkumab (GUS), risankizumab (RIS)] and an IL-12/23 inhibitor [ustekinumab (UST)] in patients with purely axial psoriatic arthritis (PsA) or mixed PsA (both axial and peripheral involvemen...